Kalkidan T. Shiferaw

Kalkidan Shiferaw practices at M Health Fairview St. John's Hospital in Maplewood, Minnesota, part of M Health Fairview.

Kalkidan Shiferaw's NPI, 1467942151, was assigned on May 17, 2018. Kalkidan Shiferaw holds Tennessee license 62679.

Kalkidan Shiferaw's primary practice is M Health Fairview St. John's Hospital, at 1575 Beam Avenue, Maplewood, MN 55109 in Ramsey County. The practice phone is (651) 232-7000.

Kalkidan Shiferaw's primary practice is M Health Fairview St. John's Hospital in Maplewood, Minnesota, part of M Health Fairview. Kalkidan Shiferaw is also affiliated with Brookdale Hospital Medical Center. The medical group on file is M Health Fairview St. John's Hospital. Dmand AI also links Kalkidan Shiferaw to 5 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kalkidan Shiferaw practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Kalkidan Shiferaw's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Kalkidan Shiferaw is licensed in Tennessee.

CMS data shows 458 Medicare services from Kalkidan Shiferaw across 5 procedure codes in 2024, for 175 Medicare patients. Medicare paid $38,239 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 175 Medicare patients who saw Kalkidan Shiferaw in 2024. The largest group is 75 to 84, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kalkidan Shiferaw's median patient age at 76, with 47% women.

In 2024, Kalkidan Shiferaw wrote 283 Medicare Part D claims for 101 patients. 83% of them were for generic drugs. CMS names the drug for 104 of them, across 6 drugs with 11 or more claims each, at $10,899 in total drug cost. In 2023, CMS named 22 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Kalkidan Shiferaw for performance year 2024, reported as part of a group. Kalkidan Shiferaw accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Kalkidan Shiferaw from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $33.